Skip to main content

Table 1 Efficacy and safety data from the three trials comparing dabigatran etexilate with the European enoxaparin dose as thromboprophylaxis following elective total hip or knee replacement surgery [1921]

From: Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants

  220 mg dabigatran etexilate initiated post-surgery 150 mg dabigatran etexilate initiated post-surgery 40 mg enoxaparin initiated 12 h pre-surgery
RE-MODEL™trial (knee replacement)
Total VTE and all-cause mortality (primary efficacy end-point) 183/503 (36.4%) 213/526 (40.5%) 193/512 (37.7%)
Major bleeding 10/679 (1.5%) 9/703 (1.3%) 9/694 (1.3%)
RE-NOVATE ® trial (hip replacement)
Total VTE and all-cause mortality (primary efficacy end-point) 53/880 (6.0%) 75/874 (8.6%) 60/897 (6.7%)
Major bleeding 23/1146 (2.0%) 15/1163 (1.3%) 18/1154 (1.6%)
RE-NOVATE ® II trial (hip replacement)
Total VTE and all-cause mortality (primary efficacy end-point) 61/792 (7.7%) - 69/785 (8.8%)
Major bleeding 14/1010 (1.4%) - 9/1003 (0.9%)
  1. VTE venous thromboembolism